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Background. Subcutaneous administration of hepatitis B immunoglobulin (HBIg) is effective in preventing hepatitis B virus
(HBV) recurrence after liver transplantation, but early conversion to subcutaneous administration is undocumented.Methods.
In a prospective study, patients transplanted for terminal liver disease due to HBV infection who were HBV DNA-negative at trans-
plant were switched by week 3 posttransplantation from intravenous to subcutaneous HBIg (500 or 1000 IU weekly or fortnightly,
adjusted according to serum anti-HBs trough level) if they were HBsAg- and HBV-DNA negative at time of switch. All patients con-
comitantly received nucleos(t)ide analogue antiviral therapy. Primary endpoint was failure rate by month 6, defined as serum anti-
HBs of 100 IU/L or less or HBV reinfection despite serum anti-HBs greater than 100 IU/L. Results. Of 49 patients treated, 47
(95.9%) continued treatment until month 6. All patients achieved administration by a caregiver or self-injection by week 14. No
treatment failures occurred. Mean anti-HBs declined progressively to month 6, plateauing at a protective titer of approximately
290 IU/L. All patients tested for HBV DNA remained negative (45/45). Only 1 adverse event (mild injection site hematoma) was
assessed as treatment-related. Conclusions. Introduction of subcutaneous HBIg administration by week 3 posttransplanta-
tion, combined with HBV virostatic prophylaxis, is effective and convenient for preventing HBV recurrence.
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1508 Transplantation ■ July 2016 ■ Volume 100 ■ Number 7 www.transplantjournal.comThe introduction of regular intravenous administrationof hepatitis B immunoglobulin (HBIg) for hepatitis B
virus (HBV) reinfection prophylaxis in the early 1990s led
to a dramatic reduction in HBV recurrence after liver trans-
plantation1-3 such that 5-year survival following transplan-
tation for hepatitis B infection now approaches 80%.4,5
Combination prophylaxis with HBIg and nucleoside or nu-
cleotide antiviral drugs is more effective than either treat-
ment alone6,7 and is generally considered the standard of care
in at-risk patients5,8,9 although routine use of HBIg is not
universal. Low-dose or fixed-term intravenous HBIg regi-
mens have been widely adopted following evidence that effi-
cacy is preserved with significant cost savings compared with
early high-dose protocols.10 Some centers instead use intra-
muscular administration of HBIg, which again maintains
efficacy at a lower cost than conventional intravenous regi-
mens.11-15 Most intramuscular HBIg products, however, are
not licensed for prevention of HBV reinfection, and the intra-
muscular route is contraindicated in patients with coagulopa-
thies or who are receiving oral anticoagulant therapy, as well
as being painful to administer.
Subcutaneous administration of HBIg in combination
with antiviral therapy is an appealing alternative that offers
patients the option to self-administer at home. A randomized,
single-dose trial in healthy volunteers has confirmed that the
pharmacokinetics of HBIg are similar using either subcu-
taneous or intramuscular injection.16 Clinical studies have
shown that the serum anti-HBs concentration remains above
100 IU/L in patients treated with subcutaneous HBIg,17-19
a threshold regarded as the minimum for effective preven-
tion of HBV reinfection in HBV-DNA–negative patients,20,21
with few adverse events.22 Previous studies, in which patients
were switched from intravenous to subcutaneous HBIg have
usually undertaken the conversion at 6 months posttrans-
plantation or later.18,19,23 However, it would be convenient
for patients if the transition to subcutaneous HBIg could
be undertaken during the initial hospital stay, avoiding the
need for additional clinic visits and patient training by nurs-
ing staff in the ambulatory departments. Data on early switch
to subcutaneous administration are sparse.24
The aim of the current study was to assess the preven-
tion of HBV reinfection in HBV-DNA–negative liver trans-
plant patients after initiation of subcutaneous HBIg by week
3 posttransplantation.MATERIALS AND METHODS
Study Design and Conduct
This was a prospective, open-label, single-arm, phase III,
6-month study in which patients undergoing liver transplan-
tation due to HBV infection were switched from intravenous
HBIg to subcutaneous administration by week 3 posttrans-
plantation. The study was conducted at 17 centers in Italy,
Spain, France, and the United Kingdom during December
2012 to September 2014.
The study protocol was approved by the institutional re-
view board at each site and was conducted in accordance
with the principles of Good Clinical Practice and the Dec-
laration of Helsinki. All participants provided written in-
formed consent.Patient Population
Patients aged 18 to 75 years undergoing a first or sub-
sequent liver transplantation due to HBV infection were
eligible to enter the study if they met the following criteria:
HBV-DNA negative at time of transplant and at the time of
switch to subcutaneous HBIg; HBsAg negative with serum
HBs antibody concentration of 400 IU/L or greater at week
1 or 2 posttransplantation, that is, the time of switch to sub-
cutaneous administration and stable clinical condition in the
opinion of the investigator. Patients were converted to sub-
cutaneous HBIg as soon as they became HBsAg-negative, if
serum HBs antibody concentration is 400 IU/L or greater.
The threshold of 400 IU/L was selected to ensure an ade-
quate safety margin above 100 IU/L, considering the mini-
mum for effective HBV reinfection prevention.8 The key
exclusion criteria were retransplantation due to viral recur-
rence, positive HIV, or hepatitis C test at time of transplant,
and a donor positive for HBsAg. Patients positive for hepati-
tis D virus could be enrolled, as could patients without liver
failure who underwent transplantation because of hepatocel-
lular carcinoma due to hepatitis B infection.
Study Treatment
Patients who met the eligibility criteria were converted
from intravenous standard HBIg to subcutaneous HBIg
(Zutectra; Biotest AG, Dreieich, Germany) at approximately
days 8 to 11 or 15 to 18 posttransplantation, according to
their HBsAg status, that is, switch took place as soon as
the patient's serum became free of HBsAg from day 8 on-
ward. Subcutaneous HBIg was administered once a week
or once every 2 weeks, at the discretion of the investigator,
until month 6 posttransplantation at a maximum dose of
1000 IU (2 mL). The dose was adjusted based on the serum
anti-HBs concentration, at the discretion of the study investi-
gator. In exceptional cases, a dose of up to 1500 IU/L was
permissible. In the event of serum HBs antibody con-
centration decreasing to 100 IU/L or lower (even after dosage
adaptation), patients were to be withdrawn from further par-
ticipation in this study.
After week 4 posttransplantation, administration of HBIg
could be undertaken by the patient or a caregiver after assess-
ment in the transplant unit if they complied with the subcu-
taneous injection technique after a training program, and if
anti-HBs trough level was greater than 100 IU/L. Compliance
with theHBIg dosing regimenwasmonitored by documenta-
tion in a patient diary that was checked at each study visit
and confirmed by measurement of anti-HBs titers.
Concomitant antiviral therapy with a nucleoside/nucleotide
analogue was administered to all patients according to lo-
cal practice.
Data Collection and Analysis
Serum HBs antibody concentrations were determined be-
fore HBIg administration once a week for the first 4 weeks,
once every week or 2 weeks (at the discretion of the inves-
tigator) to week 9, then once every 4 weeks. Recurrence of
HBV infection of the transplanted liver (based on HBsAg
positivity and clinical symptoms), laboratory data, and the
occurrence of adverse events were documented throughout
the 6-month study.
Patient diaries were use to record compliance with home ad-
ministration of subcutaneous HBIg. Additionally, the diaries
TABLE 1.
Baseline characteristics (n = 49)
Age: mean (SD), y 52.2 (9.2)
Male sex, n (%) 41 (83.7)
White, n (%) 45 (91.8)
Indication for liver transplantation, n (%)a
HBV-induced cirrhosis 45 (91.8)
Hepatocellular carcinoma 24 (49.0)
Acute liver failure 1 (2.0)
Retransplantation 3 (6.1)
Other 4 (8.2)
Coinfection with hepatitis D virus, n (%) 21 (42.9)
Antiviral therapy pretransplant, n (%) 40 (81.6)
HBV-DNA negative at time of transplant, n (%) 49 (100.0)
a More than 1 reason could be selected.
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ing questions: “Was taking HBIg by subcutaneous injection
convenient for you?” “In your opinion, is the subcutaneous
application easy to handle?” “Overall, were you satisfied with
your HBIg treatment?”
The primary endpoint of the study was failure rate by
month 6, defined as serum anti-HBs of 100 IU/L or less or
HBVreinfection (ie, HBsAg positivity and clinical symptoms)
despite serum anti-HBs greater than 100 IU/L. The sample
size calculation estimated that a population of 40 evaluable
patients would provide 84%power to observe a 3.5% failure
rate with a 2-sided 95% confidence interval (CI) of 16.3%
(0.6-16.9) based on the assumption that the failure rate
would not exceed 5%. The literature indicates that intrave-
nous or intramuscular administration of HBIg can effectively
maintain ant-HBs levels above 100 IU/L11,12,25,26 and that
combination therapy with antiviral agents reduces the rein-
fection rate to less than 10%.9,11,17,27
For the primary endpoint, a 2-sided 95% CI was calcu-
lated using the Clopper-Pearson method. All other variables
were analyzed descriptively, with 95% CI values where ap-
propriate. In the event of missing efficacy data, the last obser-
vation carried forward principle was applied.
The safety population comprised all patients who re-
ceived at least 1 dose of subcutaneous HBIg. The intention-to-
treat population comprised all patients who received at
least 1 dose of subcutaneous HBIg and provided at least
1 postdose efficacy assessment. All patients met the criteria
for inclusion in both populations.
All statistical analyses were performed using SAS soft-
ware (Version 8.2 or higher).RESULTS
Patient Population
In total, 75 patients were recruited, of whom 19 were ex-
cluded before the screening visit because an adequate number
of evaluable patients had already entered the study (Figure 1).
Seven patients did not meet the eligibility criteria at screen-
ing, such that the study population comprised 49 patients,
all of whom were treated with subcutaneous HBIg (Table 1).
Two patients discontinued the study prematurely: 1 was lost
to follow-up and 1 discontinued due to graft rejection.FIGURE 1. Patient disposition.The majority of patients were men (41/49, 83.7%) and
white (45/49; 91.8%). Forty-five patients were transplanted
due to HBV-induced cirrhosis (91.8%), with hepatocellular
carcinoma listed as a cause of transplantation in 24 cases
(49.0%). Twenty-one patients (42.9%) were coinfected with
hepatitis D. Five patients (10.2%) experienced graft rejection
during the study.
Before the informed consent, 39 patients were HBV
DNA-negative. Hepatitis B virus DNA was undetectable in
48 patients both at the point of informed consent signa-
ture and time of liver transplant, as per the inclusion criteria
(information was missing in 1 patient). As per protocol, all
49 patients were HBsAg-negative at the time of the first dose
of subcutaneous HBIg. All donors were HBsAg-negative.
Forty patients (81.6%) were receiving antiviral therapy be-
fore transplantation.HBIg Therapy and Concomitant Medication
Subcutaneous HBIg was started during days 8 to 11 post-
transplantation in 37 patients and during days 15 to 18 in
the remaining 12 patients. At study entry, a weekly treatment
schedule was documented in 20 patients. The other 29 patients
received treatment every 2 weeks. The initial subcutane-
ous dose was 500 IU in 19 of the 20 patients dosed
weekly, and in 22 of the 29 patients treated once every
2weeks. By the final visit, the proportion of patients requir-
ing a dose of 1000 IU had increased slightly in both
the weekly and biweekly dosing groups (Table 2). In to-
tal, 13 doses of 1500 IU were administered in 5 patients
during the study.
Subcutaneous HBIg could be injected at home by the pa-
tient or a caregiver (eg, family member or other nonpro-
fessional care worker) after week 4 posttransplantation.
All patients achieved administration by a caregiver or self-
injection by week 14 and continued until the end of the study
(except for 1 patient at 2 study visits).
All patients received concomitant antiviral therapy, com-
prising entecavir (n = 27), lamivudine (n = 12), tenofovir
(n = 10), and adefovir (n = 1).
The immunosuppression regimen included tacrolimus in
all except 1 patient. Othermaintenance immunosuppressants
comprised mycophenolate mofetil (n = 29), everolimus
(n = 16), sirolimus (n = 2) and cyclosporine (n = 2 [including
TABLE 2.
Subcutaneous HBIg administration (n = 49)
Dosing interval
Once a week 20 (40.8)
Once every 2 wk 29 (59.2)
Starting dose, IU
Once a week
500 19 (38.8)
1000 1 (2.0)
Once every 2 wk
500 22 (44.9)
1000 5 (10.2)
1500 2 (4.1)
Final dose, IU
Once a week
500 15 (30.6)
1000 5 (10.2)
Once every 2 wk
500 20 (40.8)
1000 8 (16.3)
1500 1 (2.0)
1510 Transplantation ■ July 2016 ■ Volume 100 ■ Number 7 www.transplantjournal.com1 patient converted from tacrolimus]), with corticosteroids
in 40 patients.
Efficacy
All patients maintained serum HBs antibody concentra-
tions greater than 100 IU/L and remained HBsAg-negative
throughout the 6-month study. Thus, no treatment failures
occurred (0.0 [95% CI, 0.0-0.0725]).
Figure 2 illustrates the course of anti-HBs levels during
the study. Mean (SD) anti-HBs was 1095 (527) IU/L before
the first dose of subcutaneous HBIg, and 292 (147) IU/L at
the end of the 6-month study. Mean anti-HBs peaked at
the time of the second subcutaneous dose (mean [SD] 1112
[776] IU/l), then declined progressively to month 6, plateauing
at approximately 290 IU/L. After the first dose of subcutane-
ous HBIg, the minimum anti-HBs level observed in any pa-
tient at any time point was 115 IU/L (Figure 2). MaximumFIGURE2. Box-and-whisker plot of anti-HBs serum level. Vertical lines in
boxes indicate standard deviation values, and horizontal lines indicate m
baseline; SD, second dose; FV, final visit.values ranged from 5017 (after the first dose) to 1000 IU/L
(from week 8 onward).
One patient experienced transient splenomegaly, which
was present before the first dose of subcutaneous HBIg on
day 7. No clinical symptoms consistent with HBV reinfec-
tion were observed during the study.
Mean (SD) values for alanine transaminase, aspartate ami-
notransferase, γ-glutamyltransferase, alkaline phosphatase
and total bilirubin at the final study visit were 30.5 (22.4)
IU/L, 25.5 (11.1) IU/L, 49.7 (52.9) IU/L, 105.7 (49.4) IU/L,
and 0.61 (0.3) mg/dL, respectively. No liver function test
showed a clinically relevant abnormality in more than
2 patients at the final visit.
Safety and Tolerability
Forty-five patients reported 1 or more adverse event during
the study, 1 of which (graft rejection) led to study discon-
tinuation but was not considered related to study treatment.
No adverse event resulted in a change to the HBIg dose.
Only 1 adverse event, a mild injection site hematoma, was
assessed as treatment-related, and HBIg administration was
not altered as a consequence. No serious drug-related ad-
verse events occurred.
No patient showed clinically abnormal levels of IgG, IgA,
or IgM at the final study visit.
Patient Attitudes
All patients responded “yes” to the question “Overall,
were you satisfied with your HBIg treatment?” at all study
visits. The handling of the subcutaneous application was
assessed to be easy (yes/no response) by 92% of patients by
week 4, increasing to 100% from week 16 onward. Further-
more, patient diaries indicated 100%compliance throughout
the study.DISCUSSION
This is the first study to investigate the efficacy of starting
subcutaneous HBIg for HBV reinfection prophylaxis, dosed
according to serum anti-HBs trough level, by week 3 afterdicatemaximum andminimumvalues, crosses indicatemean values,
edian values. Maximum values above 3000 IU/L were truncated. BL,
© 2016 Wolters Kluwer De Simone et al 1511liver transplantation. In this cohort of 49 patients receiving
concomitant antiviral therapy, all of whom were HBV
DNA-negative at time of transplant, early switch to weekly
or fortnightly subcutaneous administration maintained se-
rum anti-HBs at a level that effectively prevented HBV rein-
fection in all patients. After switch to subcutaneous HBIg,
no patient had an anti-HBs level below 100 IU/L. Most pa-
tients were maintained on a subcutaneous dose of 500 IU
once a week (~30%) or once every 2 weeks (~40%). There
were no cases of HBV recurrence and no laboratory or path-
ological signs characteristic of HBV reinfection of the graft
during the 6-month trial other than 1 case of splenomegaly
which was present before the first dose of HBIg.
The study did not seek to determine the effectiveness of
HBIg therapy per se, and thus did not include an HBIg-free
control arm. Instead, the aim was to examine outcomes with
very early switch to the subcutaneous route of admin-
istration, instead of extended intravenous therapy or use of
intramuscular injection. The subcutaneous route facilitates
administration of HBIg at home, an approach that is con-
venient for patients and reduces staff time. A trial compar-
ing intramuscular to subcutaneous HBIg injection reported
that patients found subcutaneous administration to be less
painful and preferred it to the intramuscular route.17 Typi-
cally, conversion from intravenous to subcutaneous adminis-
tration has been carried out no earlier than 6 months after
liver transplantation.18,19,23 In 1 small pilot study, 12 de novo
liver transplant patients (all of whom were HBV DNA-
negative and HBsAg-positive before transplantation) were
converted at a median of 25 days' posttransplantation from
intravenous HBIg (30000 IU) to subcutaneous therapy.24
The subcutaneous dose was 500 or 1000 IU per week, ac-
cording to body weight.24 In that series, the anti-HBs titers
remained at 150 UI/L or above throughout 6 months of
follow-up, with no viral breakthrough. These results are
consistent with our own findings in which switch to subcuta-
neous therapy took place even earlier.
The dosage regimen for HBIg is currently a matter of con-
troversy, particularly in relation to proposals that low-dose
treatment should be started during the anhepatic phase.14
In the current study, the subcutaneous dosage regimen was
flexible, within protocol-defined limitations: 500 to 1000 IU
was selected according to anti-HBs trough levels, with the
starting dose also depending on the HBsAg and anti-HBsAb
status achievedwithin the first week posttransplantation dur-
ing intravenous HBIg administration. This individualized
approach is consistent with the product license for marketed
intravenous HBIg preparations, which states that patients
1 week after liver transplantation should receive doses of
HBIg as high as necessary to maintain antibody levels above
100 to 150 IU/L in HBV-DNA negative patients. There was
a clear trend in our population for the anti-HBs levels
reached throughout and after the intravenous dosing phase
to be lower than anticipated based on the pharmacokinetic
characteristics of intravenous HBIg. This was duly accounted
for by the investigators through frequent uptitration of the
subcutaneous dose when the serum anti-HBs levels were
lower or declined faster than might have been expected. In
general, such increases achieved higher anti-HBs levels. In
the absence of a protocol-specified dosing algorithm, the sub-
cutaneous dose need not be increased if the anti-HBs titer
is close to 100 IU/L, avoiding the potential overtreatmentin some patients that could occur with a fixed treatment reg-
imen. This, additionally, could be expected to yield potential
cost savings.
Previous studies have demonstrated that home administra-
tion of subcutaneous HBIg is effective.18,19,23 A single-arm
18-week trial undertaken in 23 liver transplant patients has
shown that conversion from monthly intravenous HBIg to
self-administered weekly subcutaneous therapy maintained
trough anti-HBs concentration above 100 IU/L in all cases.18
In that series, all patients were a minimum of 3 months post-
transplantation at the time of conversion. A larger study
(n = 135), in which all patients were at least 12 months post-
transplantation, confirmed that anti-HBs concentration con-
sistently remained above 100 IU/L using self-administered
weekly subcutaneous HBIg throughout a 48-weekmonitoring
period.19More recently, an observational study in 61 patients,
who were converted to subcutaneous HBIg at a median of
5.7 months posttransplantation and self-administered at home,
found an anti-HBs serum concentration below 100 IU/L
at 1 or more points in 4 patients.23 In each case, however,
HBIg treatment had been interrupted by the investigator in
response to declining anti-HBs levels, and lack of efficacy
or noncompliance was not the cause of low anti-HBs levels.
In our study, there was full compliance with the prescribed
once weekly or once fortnightly regimen and the serum
HBs antibody concentration was above 100 IU/L throughout
the study in all patients. In addition, it has been shown in
liver transplant patients receiving combination prophylaxis
with HBIg plus a nucleos(t)ide inhibitor that a serum anti-
HBs level of 50 to 100 IU/L is protective in the medium
term.14 This suggests that outside clinical trials, this target
level of anti-HBs after the first few months posttransplanta-
tion could be sufficient for effective prophylaxis.
Subcutaneous HBIg was well tolerated. The only ad-
verse event related to subcutaneous HBIg was a mild in-
fection site hematoma. No patient discontinued study
drug due to treatment-related adverse events, consistent
with previous reports.18,23 The regimen was well accepted
by patients: all participants who commented at the end of
the 6-month study found subcutaneous administration to
be convenient.
The findings from this prospective, multicenter study
indicate that introduction of subcutaneous HBIg adminis-
tration by week 3 after liver transplantation, dosed ac-
cording to serum anti-HBs trough level and combined
with HBV virostatic therapy, is an effective, safe and
convenient strategy for preventing HBV recurrence after
liver transplantation.ACKNOWLEDGMENTS
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